Higher selumetinib exposure appears to be associated with treatment-related adverse effects in pediatric NF1 patients. These findings support the potential role of TDM in optimizing selumetinib dosing and provide a preliminary therapeutic AUC range for individualized treatment strategies. Larger multicenter studies are needed to validate these results and refine exposure-guided dosing approaches.
Kovács et al. (Mon,) studied this question.